Lumosa Therapeutics Co., Ltd. (TPEX:6535)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
152.00
+1.00 (0.66%)
Jun 26, 2025, 11:42 AM CST
-31.07%
Market Cap 25.66B
Revenue (ttm) 43.59M
Net Income (ttm) -413.35M
Shares Out 168.82M
EPS (ttm) -2.52
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 52,228
Average Volume 224,989
Open 155.00
Previous Close 152.00
Day's Range 151.50 - 155.00
52-Week Range 129.00 - 400.00
Beta -0.02
RSI 39.40
Earnings Date Aug 8, 2025

About Lumosa Therapeutics

Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops therapies and solutions for neurological and oncological diseases in Taiwan, Asia, the Americas, and Europe. The company offers Naldebain (LT – 1001), an analgesic injection for severe pain relief after surgery. It is developing LT3001, which is in Phase II clinical trial for the treatment of acute ischemic stroke; LT5001 that has completed Phase I clinical trial for uremic pruritus; LT6001 that is in pre-clinical trials for neurological disorders; and LT2003, whic... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 43
Stock Exchange Taipei Exchange
Ticker Symbol 6535
Full Company Profile

Financial Performance

In 2024, Lumosa Therapeutics's revenue was 39.15 million, a decrease of -31.21% compared to the previous year's 56.92 million. Losses were -424.78 million, 78.4% more than in 2023.

Financial Statements

News

There is no news available yet.